Back to Results
First PageMeta Content
Organic chemistry / Circulatory system / Benzofurans / Cardiac electrophysiology / Amiodarone / Atrial fibrillation / Merck & Co. / Vernakalant / Tachycardia / Chemistry / Cardiac dysrhythmia / Antiarrhythmic agents


News Release ____________________________________________________________________________ FOR IMMEDIATE RELEASE Merck Media Contact:
Add to Reading List

Document Date: 2011-07-26 06:58:59

Open Document

File Size: 29,03 KB

Share Result on Facebook

City

Tokyo / DEERFIELD / /

Company

Merck & Co. Inc. / Astellas Pharma Inc. / Merck / Schering-Plough / 4About Astellas Astellas US LLC / Merck Sharp & Dohme Corp. / Astellas US LLC / Cardiome Pharma Corp. / /

Country

Mexico / Norway / United States / Iceland / Canada / /

Event

FDA Phase / M&A / Business Partnership / /

Facility

Astellas WHITEHOUSE STATION / /

IndustryTerm

animal health products / health solutions / pharmaceutical / healthcare / pharmaceutical industry regulation / pharmaceutical products / /

MedicalCondition

ventricular tachycardias / sinus node dysfunction / severe bradycardia / acute atrial fibrillation / hypersensitivity / ventricular arrhythmia / Hypotension / congestive heart failure / valvular heart disease / atherosclerosis / heart block / dysgeusia / aortic stenosis / onset atrial fibrillation / acute coronary syndrome / myocardial infarction / heart failure / Atrial fibrillation / /

MedicalTreatment

cardiac surgery / surgery / biologic therapies / /

Organization

European Union / Securities and Exchange Commission / /

Person

Masao Yoshida / Michael Mendelsohn / Ian McConnell / /

/

Position

President / franchise head / cardiovascular and atherosclerosis research / Global Category Leader / global healthcare leader / CEO / senior vice president / franchise head / Private / /

Product

European Union / BRINAVESS™ (vernakalant) / /

ProvinceOrState

New Jersey / Illinois / /

URL

www.sec.gov / www.merck.com / www.astellas.us / /

SocialTag